| Typicality: | 0.452 |
| Saliency: | 0.473 |
| over an 8 week period | 6 | temporal |
| to evaluate tolerability | 5 | purpose |
| in patients | 5 | other |
| trial → be designed to assess → efficacy | 19 |
| trial → be designed to evaluate → efficacy | 12 |
| trial → be designed to test → efficacy | 8 |
| trial → be designed to measure → efficacy | 7 |
| trial → be to evaluate → efficacy | 4 |
| trial → be designed to demonstrate → efficacy | 4 |
| trial → be designed to examine → efficacy | 3 |
| negative | neutral | positive |
| 0.058 | 0.815 | 0.127 |
| Raw frequency | 57 |
| Normalized frequency | 0.473 |
| Modifier score | 0.500 |
| Perplexity | 142.698 |